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Abstract 
Plasma Cell Neoplasms are a family of disorders 
characterized by clonal proliferation of a plasma cell. 
These include: Multiple Myeloma (MM) and its 
precursor states MGUS and SMM, solitary osseous 
or non-osseous plasmacytoma, POEMS syndrome, 
heavy chain disease, and systemic AL amyloidosis. 
The hallmark characteristics of plasma cell 
neoplasms are: (1) histopathologic confirmation of 
excess clonal plasma cells; and (2) excessive 
production and secretion of an intact monoclonal 
protein (M spike) or free light chains (FLC; not in 
association with heavy chains) in the serum and/or 
urines. Plasma cell neoplasms can be premalignant 
(e.g. MGUS) or malignant (e.g. MM). 
KEYWORDS 
Plasma cell neoplasia, multiple myeloma, 
plasmacytoma 
Clinics and pathology 
Disease 
Plasma Cell Neoplasia is an umbrella term for 
diseases resulting from the excessive proliferation of 
plasma cells.  These include: Multiple Myeloma 
(MM) and its precursor statesmonoclonal 
gammopathy of undetermined significance (MGUS) 
and smoldering multiple myeloma (SMM), solitary 
osseous or non-osseous plasmacytoma, POEMS 
syndrome, heavy chain disease, andsystemic AL 
amyloidosis. The hallmark characteristics of plasma 
cell neoplasms are: (1) histopathologic confirmation 
of excess clonal plasma cells; and (2) excessive 
production and secretion of an intact monoclonal 
protein (M spike) or free light chains (FLC; not in 
association with heavy chains) in the serum and/or 
urines. Plasma cell neoplasms can be premalignant 
(e.g. MGUS) or malignant (e.g. MM). 
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Phenotype/cell stem origin 
MGUS, SMM, 
MM 
Antigen-selected, post-germinal 
center, terminally differentiated 
plasma cell (Anderson and Carrasco 
2011) 
Plasmacytoma 
Well defined, monoclonal proliferation 
of plasma cells that occurs either (1) 
inside (solitary bone plasmacytoma) or 
(2) outside (extramedullary 
plasmacytoma) the bone (Chang et al, 
2014). 
Heavy chain 
disease (HCD) 
Group of three rare and clinically 
distinct B-cell neoplasms (alpha, 
gamma, mu HCD) that result in the 
excessive production of abnormal 
immunoglobulin heavy chain incapable 
of binding light chains (Bianchi et al 
2014). Alpha HCD is associated with 
immunoproliferative small intestinal 
disease with features resembling 
MALT lymphoma. Gamma HCD has 
features resembling Waldenstrom 
macroglobulinemia (WM) while Mu 
HCD has features resembling CLL 
(Bianchi et al 2014). 
POEMS 
syndrome 
Rare paraneoplastic syndrome caused 
by underlying plasma cell neoplasm. 
Characterized by 
polyradiculoneuropathy, the presence 
of clonal plasma cells, sclerotic bone 
lesions, elevated vascular endothelial 
growth factor, and Castleman disease. 
Other minor features include: 
organomegaly, endocrinopathy, 
characteristic skin changes, 
papilledema, extravascular volume 
overload, and thrombocytosis 
(Dispenzieri A, 2014).  
 
Etiology 
Etiology not known. Possible (unconfirmed and 
controversial) risk factors include:  
 
 Environmental factors such as radiation exposure, 
occupational exposure (agricultural, chemical, 
metallurgical, rubber plant, pulp, wood, paper), and 
chemical exposure (formaldehyde, epichlorohydrin, 
Agent orange, hair dyes, paint sprays, asbestos). 
 Viral infection: Herpesvirus 8 infection noted in 
some patients with MM, but there are no data to 
substantiate a causative link; 
 Genetic predisposition: Patients with a siblings or 
other first-degree relatives who have one of these 
diseases are more likely to develop it as well.  
 
MGUS, SMM, 
MM 
Transformation of normal plasma cells 
into myeloma cells thought to result 
from one of two primary genetic 
events: either (1) hyperdiploidy or (2) 
aberrant class switch recombination 
(CSR). Secondary cytogenetic 
abnormalities result in progression of 
MGUS to SMM, MM, and plasma cell 
leukemia (Ho et al, 2017). 
Plasmacytoma 
Similar to MM in that cell of origin is 
plasma cell; expresses antigens 
associated with myelomonocytes 
(CD33), megakaryocytes (GpIIb/IIIa), 
erythroid cells (glycophorin) (Nikhil 
Sangle, 2011). 
Heavy chain 
disease 
Deletions, insertions or point 
mutations in the constant 1 (CH1) 
domain of the IgH are acquired during 
the process of somatic hypermutation. 
These mutations typically result in: (1) 
inability to bind and reach a stable 
quaternary structure with IgL chain; (2) 
inability to bind to the chaperone heat 
shock protein 78 (HSP 78), which 
mediates proteasomal degradation of 
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free IgH (Goossens et al., 1998). As a 
result, free IgH can be detected in both 
serum and urine. Pathogenesis is 
unknown. Autoimmune disease is 
present in ~25% of patients and 
typically precedes by many years the 
onset of gamma HCD (Wahner-Roedler 
et al., 2003). 
POEMS 
syndrome 
Etiology unknown. Major feature of 
POEMS syndrome is the chronic 
overproduction of pro-inflammatory 
cytokines (e.g. VEGF; IL6). Thought to 
be a paraneoplastic syndrome caused 
by an underlying plasma cell disorder 
(Zou et al 2015). 
 
Epidemiology 
Disease MGUS SMM MM Plasmacytoma 
POEMS 
syndrome 
Heavy-chain disease 
Incidence 
3.76 per 
100,000 
persons; 
Progresses to 
MM at rate of 
~1.4% per year 
0.9 per 
100,000 
persons 
~30,280 new 
cases/year; 6.6 
per 100,000 
persons (US) 
~1,543 new 
cases/year; 0.3 per 
100,000 persons 
(US)  
~700 new 
cases/year 
(US) 
A: Most common; G: 
Intermediate; M: 
Least common 
Prevalence 
> 50y: 3.2%; M: 
3.7%; F: 2.9% 
Unknown 118,539 (US) N/A N/A 
A: >400; G: ~130; M: 
~35 
Overall 
survival 
5 yr: 78.3% 
Median OS: 
54.8 months 
(2003-2007); 
67.1% (2008-
2011) 
5 yr: 49.6% 
SBP: 71.9% (5y); 
EMP: 88.2% (5y) 
5 yr: 60% 
A: ~67% (5yr); G: 
7.4yr (median); M: 
~2yr (median) 
Median age 
at 
diagnosis 
70y (<2% 
younger than 
40y) 
67y 69y 55-65y 
48y (men); 
59y 
(women) 
?: 20-30y; G: 51-68y; 
M: 58y 
Ethnicity 
Twice as 
common in 
African 
Americans as in 
the Caucasian 
population; low 
in Asian 
countries 
Black > 
Asian/pacific 
islander> white  
Twice as 
common in 
African 
Americans as in 
the Caucasian 
population; low 
in Asian 
countries 
30% higher 
incidence rate in 
African Americans; 
Also seen in 
Caucasians and low 
in Asian countries. 
No known 
racial 
connection. 
A: Mediterranean, 
North African, 
Middle Eastern; G: 
Worldwide 
distribution; M: 
Mostly Caucasian 
Gender M > F M> F M > F (1.6:1) M > F (2-3:1) M > F (2.5:1) 
A: M > F; G: F > M; 
M: M > F 
 
Clinics 
Plasma Cell 
Neoplasm 
Clinical Features 
MGUS, SMM, 
MM 
MGUS: Asymptomatic 
SMM: Asymptomatic 
MM: Hypercalcemia, renal failure, 
anemia, bone disease (CRAB criteria) 
Plasmacytoma 
As space occupying lesions, the 
symptoms of plasmacytoma vary 
based on the location of the tumor. 
Plasmacytomas located in the brain 
(e.g. solitary craniocerebral 
plasmacytoma or EMP of the brain) 
can cause headaches, seizures, and 
paralysis, while plasmacytomas in the 
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rib may cause non-cardiac chest pain 
that is pleuritic in nature. 
Generally speaking, a common yet 
nonspecific clinical symptom of SBP is 
pain. Motor and sensory deficits can 
also occur, secondary to nerve 
impingement from compression 
fractures (Guo et al, 2013). 
Complications of SBP include 
pathological fractures due to lytic bone 
disease.  
EMP, on the other hand, usually 
manifests itself in the upper 
respiratory tract and oral cavity, 
symptoms often include epistaxis, sore 
throat, rhinorrhea, and hemoptysis 
(Chang et al, 2014)(Galieni et al, 2000) 
HCD 
A: Digestive, lymphomatous, or 
respiratory forms 
G: Disseminated (generalized 
lymphadenopathy); localized (either 
isolated BM involvement or localized 
extra-nodal disease); minority with 
only autoimmune disease 
M: Splenomegaly, hepatomegaly, 
lymphadenopathy 
POEMS 
syndrome 
Polyneuropathy: 
 Symmetric distal weakness 
and paraesthesia  
 Impotence  
 Raynaud's phenomenon  
 Painful Diarrhea 
Organomegaly: 
 Hepatomegaly  
 Splenomegaly,  
 Lymphadenopathy, 
castleman disease 
Endocrinopathy: 
 Hypothyroidism##  
 Gonadal axis abnormality 
(e.g. amenorrhea)  
 Adrenal axis abnormality  
 Gynecomastia/ galactorrhea  
 Diabetes mellitus  
 Peripheral edema  
 Hyperhidrosis  
M-protein (sign) 
Skin changes: 
 Hyperpigmentation  
 Acrocyanosis and plethora  
 Hemangioma/ telangiectasia  
 Hypertrichosis  
 Thickening  
 
International Myeloma Working Group (IMWG) 
diagnostic criteria (Rajkumar, et al 2014):  
 
Plasma Cell 
Disorder  
Definition 
Progression 
rate 
Primary progression events 
Multiple myeloma 
(MM) 
(1) Clonal bone marrow plasma cells ? 10%  
OR 
(2) Biopsy proven bony or extramedullary 
plasmacytoma 
AND 
Any one or more of the following myeloma-defining 
events: 
End organ damage (CRAB) 
ï Hypercalcemia: Ca > 2.75 mmol/L (>11mg/dL) 
ï Renal insufficiency: Cr > 177 mol/L (>2mg/dL) 
ï Anemia: Hb < 100g/L or >20g/L below normal 
ï Bone lesions: One or more osteolytic lesion on 
skeletal radiography, CT, or PET/CT (if BM <10% clonal 
plasma cells, more than one bone lesion required to 
distinguish from solitary plasmacytoma with minimal 
marrow involvement) 
OR 
NA 
At the terminal stage of 
disease, evolution to 
secondary plasma cell 
leukemia is common 
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Biomarkers of malignancy 
ï ?60% clonal plasma cells on bone marrow 
examination 
ï Serum involved/uninvolved free light chain ratio of 
100 or greater, provided the absolute level of the 
involved light chain is at least 100mg/L 
ï More than one focal lesion on MRI ?5mm in size 
Smoldering 
multiple myeloma  
(SMM) 
Both criteria must be met: 
(1) Serum monoclonal protein (IgG or IgA) ?30g/L or 
urinary monoclonal protein ?500mg per 24h and/or 
clonal bone marrow plasma cells 10-60% 
AND 
(2) Absence of myeloma defining events or 
amyloidosis 
10%/year in 
the first 5 years 
MM 
Non-IgM 
monoclonal 
gammopathy of 
undetermined 
significance 
(non-IgM MGUS) 
All criteria must be met: 
(1) Serum monoclonal protein (non-IgM type) <30 g/L  
AND 
(2) Clonal bone marrow plasma cells <10% 
AND 
(3) Absence of end-organ damage such as 
hypercalcaemia, renal insu?ciency, anaemia, and bone 
lesions (CRAB) or amyloidosis that can be attributed to 
the plasma cell proliferative disorder 
1%/year 
MM, solitary 
plasmacytoma, 
immunoglobulin-related 
amyloidosis (AL, AHL, AH) 
IgM monoclonal 
gammopathy of 
undetermined 
significance 
(IgM MGUS) 
All criteria must be met: 
(1) Serum IgM monoclonal protein <30 g/L  
AND 
(2) Bone marrow lymphoplasmacytic in?ltration <10%  
AND 
(3) No evidence of anaemia, constitutional symptoms, 
hyperviscosity, lymphadenopathy, 
hepatosplenomegaly, or other end-organ damage that 
can be attributed to the underlying 
lymphoproliferative disorder 
1.5% per year 
Waldenstrom 
macroglobulinemia (WM), 
IgM MM, immunoglobulin-
related amyloidosis (AL, 
AHL, AH) 
Light-chain 
monoclonal 
gammopathy of 
undetermined 
significance 
(Light chain MGUS) 
All criteria must be met: 
(1) Abnormal FLC ratio (<026 or >165) Increased level 
of the appropriate involved light chain (increased ? 
FLC in patients with ratio >165 and increased ? FLC in 
patients with ratio <026) and  no immunoglobulin 
heavy chain expression on immuno?xation 
AND 
(2) Clonal bone marrow plasma cells <10%  
AND 
(3) Urinary monoclonal protein <500 mg/24 h 
AND 
(4) Absence of end-organ damage such as 
hypercalcaemia, renal insu?ciency, anaemia, and bone 
lesions (CRAB) or amyloidosis that can be attributed to 
the plasma cell proliferative disorder  
0.3% per year 
Light chain MM, 
immunoglobulin light-chain 
amyloidosis 
Solitary 
plasmacytoma 
All criteria must be met: 
(1) Biopsy-proven solitary lesion of bone or soft tissue 
with evidence of clonal plasma cells  
AND 
(2) Normal bone marrow with no evidence of clonal 
About 10% 
within 3 years 
MM 
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plasma cells  
AND 
(3) Normal skeletal survey and MRI (or CT) of spine 
and pelvis (except for the primary solitary lesion) 
AND 
(4) Absence of end-organ damage such as 
hypercalcaemia, renal insu?ciency, anaemia, or bone 
lesions (CRAB) that can be attributed to a 
lymphoplasma cell proliferative disorder 
Solitary 
plasmacytoma with 
minimal marrow 
involvement 
All criteria must be met: 
(1) Biopsy-proven solitary lesion of bone or soft tissue 
with evidence of clonal plasma cells  
AND 
(2) Clonal bone marrow plasma cells <10%  
AND 
(3)Normal skeletal survey and MRI (or CT) of spine and 
pelvis (except for the primary solitary lesion)  
AND 
(4) Absence of end-organ damage such as 
hypercalcaemia, renal insu?ciency, anaemia, or bone 
lesions (CRAB) that can be attributed to a 
lymphoplasma cell proliferative disorder 
60% (bone) or 
20% (soft 
tissue) within 3 
years 
MM 
POEMS syndrome 
Both #1 and #2 must be present plus 
(1) Polyneuropathy  
AND 
(2) Monoclonal plasma cell proliferative disorder 
(almost always ?)  
AND 
(3) Any one of the following three other major criteria: 
ï Sclerotic bone lesions  
ï Castleman's disease  
ï Elevated levels of VEGFA  
AND 
(4)Any one of the following six minor criteria: 
ï Organomegaly (splenomegaly, hepatomegaly, or 
lymphadenopathy) 
ï Extravascular volume overload (oedema, pleural 
e?usion, or ascites)  
ï Endocrinopathy (adrenal, thyroid, pituitary, gonadal, 
parathyroid, pancreatic) 
ï Skin changes (hyperpigmentation, hypertrichosis, 
glomeruloid haemangiomata, plethora, acrocyanosis, 
?ushing, white nails)  
ï Papilloedema  
ï Thrombocytosis/polycythaemia 
NA NA 
Systemic AL 
amyloidosis 
All criteria must be met: 
(1) Presence of an amyloid-related organ damage (eg, 
renal, liver, heart, gastrointestinal tract, soft tissue, 
lung or peripheral nerve involvement)  
AND 
(2) Positive amyloid staining by Congo red in any tissue 
(eg, fat aspirate, bone marrow, or organ biopsy)  
AND 
(3) Evidence that amyloid is light-chain-related 
established by direct examination of the amyloid using 
NA 
Some patients might 
develop MM 
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mass spectrometry-based proteomic analysis, or 
immunoelectronmicroscopy, and  
AND 
(4) Evidence of a monoclonal plasma cell proliferative 
disorder (serum or urine monoclonal protein, 
abnormal free light-chain ratio, or clonal plasma cells 
in the bone marrow) 
 
 
Multiple myeloma:  Left: Normal bone marrow; Right: Multiple Myeloma bone marrow (note: ? 10% clonal 
bone marrow plasma cells). Image taken from: http://www.keatslab.org/multiple-myeloma-info 
 
Plasmacytoma:   Left: X-ray showing solitary bone plasmacytoma located in right shoulder complicated by 
pathological fracture of the head of humerus. Right: PET/CT showing extramedullary plasmacytoma located in 
the anterior clivus 
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Waldenstrom macroglobulinemia:  Bone marrow aspirate showing increased lymphoplasmacytoid 
lymphocytes. Image taken from: https://imagebank.hematology.org/ 
 
Heavy chain disease:  In HCD, non-contiguous 
deletions in CH1 prevent binding of heavy chain to 
light chain and degradation in proteasome, and free 
heavy chains are secreted. Variably sized deletions 
also occur in the heavy chain diversity region, heavy 
chain joining region, and heavy chain variable region 
(Bianchi et al 2014). Image taken from: 
http://www.cancernetwork.com/oncology-
journal/heavy-chain-diseases-clinical-and-
pathologic-features. 
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Treatment 
Types of Treatment Available (in Italic: FDA 
approved in MM; otherwise: clinical development):  
 
Note: Specific treatment for each disease can be 
found in the various chapters in the Atlas  
 
Immunotherapy 
 Immunomodulation 
o Pembrolizumab 
o Pidilizumab 
o Nivolumab     
 T cell-based therapies 
o PVX-410 
o MM-DC vaccine 
o Anti-BCMA CAR-T cells     
 Monoclonal antibodies 
o Daratumumab 
o Elotuzumab 
o SAR 
o BT062 
o GSK2857916       
Chemotherapy 
 Conventional chemotherapy (alkylating 
agents) 
o Melphalan 
o Carmustine 
o Cyclophosphamide 
o Doxorubicin     
 Novel agents  
o Proteasome inhibitors 
 Bortezomib 
 Carfilzomib 
 Ixazomib 
 Marizomib 
 Oprozomib       
o IMiDs 
 Thalidomide 
 Lenalidomide 
 Pomalidomide       
o Histone deacetylase inhibitors 
 Panobinostat</li> 
 Vorinostat 
 Ricolinostat 
 ACY-241       
o Tyrosine kinase inhibitors 
 Ibrutinib             
 Supportive agents 
o Zoledronic acid       
Bone marrow transplantation 
 Autologous stem cell transplantation  
 Allogeneic stem cell transplantation 
 Stem cell Mobilization 
o Plerixafor 
o Cyclophosphamide       
Radiation therapy 
 Indications 
o Pre-transplantation 
o Palliation of symptoms (i.e.: pain) 
o Plasmacytoma       
Surgery 
 Indications 
o Plasmacytoma 
o Pathological fractures 
o Compression fractures       
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Prognosis 
The prognosis varies substantially depending on:  
 Stage of disease 
 Proliferation rates 
 LDH levels 
 Treatment availability: Conventional 
therapy / Targeted Therapy / High-dose 
chemotherapy 
 M protein concentration 
 Age 
 Treatment response 
 Plasmablastic histology 
 
 Poor prognosticators include:  
 
 High LDH levels 
 Hypercalcemia 
 Renal impairment 
 Large tumor burden 
 Bence-Jones proteinuria 
 Low hemoglobin value 
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